Ballast Advisors LLC Has $1.64 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Ballast Advisors LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 28.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,890 shares of the company’s stock after buying an additional 3,478 shares during the quarter. Novo Nordisk A/S comprises 0.6% of Ballast Advisors LLC’s investment portfolio, making the stock its 25th largest holding. Ballast Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,644,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after purchasing an additional 11,727,507 shares during the period. FMR LLC increased its position in shares of Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the period. Morgan Stanley increased its position in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after purchasing an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P grew its position in Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC bought a new stake in Novo Nordisk A/S in the third quarter valued at $718,995,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 0.9 %

Shares of Novo Nordisk A/S stock traded up $1.16 during trading hours on Monday, hitting $125.67. The company’s stock had a trading volume of 1,275,743 shares, compared to its average volume of 4,936,029. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The stock has a 50 day moving average of $125.93 and a 200 day moving average of $109.86. The company has a market capitalization of $563.95 billion, a PE ratio of 46.38, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Analysts predict that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This represents a yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday, April 1st. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday. They issued an “outperform” rating and a $163.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.